VTAMA® (tapinarof)
Plaque Psoriasis
Key Facts
Indication
Plaque Psoriasis
Phase
Approved
Status
Launched (Asset acquired by Organon, 2024)
Company
About Roivant Sciences
Roivant Sciences' mission is to improve health by rapidly delivering innovative medicines through its unique 'Vant' model—nimble, entrepreneurial subsidiaries. The company has demonstrated significant execution with 12 positive Phase 3 trials, 8 FDA approvals, and a successful commercial launch of VTAMA® for plaque psoriasis, which was subsequently acquired by Organon in 2024. Its strategy centers on decentralized decision-making, specialized expertise, and disciplined capital allocation to de-risk development and maximize value creation across a broad pipeline in autoimmune, pulmonary, and other diseases.
View full company profileTherapeutic Areas
Other Plaque Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| Piclidenoson (CF101) | Can Fite Biopharma | Phase III |
| Psoriasis Trial | Clinical Investigation Specialists | Not Specified |
| Encube-001 | Encube Ethicals | Phase 1/2a |
| ZL-1102 (CB001) | Crescendo Biologics | Phase 2 |
| AX-158 | Artax Biopharma | Phase 2 |
| NG-303 | Nanogen Pharmaceutical Biotechnology | Preclinical |
| Pepticom‑IL17 | Pepticom | Lead Optimization |
| JNJ-2113 | Johnson & Johnson | Phase 3 |
| Wynzora | Almirall | Marketed |
| JNJ-81201887 (via Janssen) | OmniAb | Approved |